CL2020001108A1 - Mitoflavoscinas: la fijación como objetivo de enzimas que contienen flavina elimina células madre cancerosas (cscs) al inhibir la respiración mitocondrial. - Google Patents

Mitoflavoscinas: la fijación como objetivo de enzimas que contienen flavina elimina células madre cancerosas (cscs) al inhibir la respiración mitocondrial.

Info

Publication number
CL2020001108A1
CL2020001108A1 CL2020001108A CL2020001108A CL2020001108A1 CL 2020001108 A1 CL2020001108 A1 CL 2020001108A1 CL 2020001108 A CL2020001108 A CL 2020001108A CL 2020001108 A CL2020001108 A CL 2020001108A CL 2020001108 A1 CL2020001108 A1 CL 2020001108A1
Authority
CL
Chile
Prior art keywords
mitoflavoscins
flavin
cscs
targeting
stem cells
Prior art date
Application number
CL2020001108A
Other languages
English (en)
Inventor
Michael P Lisanti
Federica Sotgia
Original Assignee
Lunella Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech Inc filed Critical Lunella Biotech Inc
Publication of CL2020001108A1 publication Critical patent/CL2020001108A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/18—Polycyclic aromatic halogenated hydrocarbons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D347/00—Heterocyclic compounds containing rings having halogen atoms as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/12—Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
    • C07D475/14—Benz [g] pteridines, e.g. riboflavin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria

Abstract

LA PRESENTE DESCRIPCIÓN SE REFIERE A COMPUESTOS QUE SE ENLAZAN A ENZIMAS QUE CONTIENEN FLAVINA E INHIBEN LA FUNCIÓN MITOCONDRIAL, REFERIDOS EN ESTE DOCUMENTO COMO MITOFLAVOSCINAS. SE DESCRIBEN MÉTODOS PARA EXAMINAR COMPUESTOS POR LA INHIBICIÓN MITOCONDRIAL Y PROPIEDADES ANTICANCEROSAS. TAMBIÉN SE DESCRIBEN MÉTODOS PARA USAR MITOFLAVOSCINAS PARA PREVENIR O TRATAR EL CÁNCER, INFECCIONES BACTERIANAS Y LEVADURA PATÓGENA, ASÍ COMO TAMBIÉN MÉTODOS PARA USAR MITOFLAVOSCINAS PARA PROPORCIONAR BENEFICIOS ANTI-ENVEJECIMIENTO. TAMBIÉN SE DAN A CONOCER COMPUESTOS ESPECÍFICOS DE MITOFLAVOSCINA.
CL2020001108A 2017-10-24 2020-04-24 Mitoflavoscinas: la fijación como objetivo de enzimas que contienen flavina elimina células madre cancerosas (cscs) al inhibir la respiración mitocondrial. CL2020001108A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762576287P 2017-10-24 2017-10-24

Publications (1)

Publication Number Publication Date
CL2020001108A1 true CL2020001108A1 (es) 2020-10-23

Family

ID=66247987

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001108A CL2020001108A1 (es) 2017-10-24 2020-04-24 Mitoflavoscinas: la fijación como objetivo de enzimas que contienen flavina elimina células madre cancerosas (cscs) al inhibir la respiración mitocondrial.

Country Status (20)

Country Link
US (1) US11497749B2 (es)
EP (1) EP3700512A4 (es)
JP (1) JP2021500374A (es)
KR (1) KR20200069365A (es)
CN (1) CN111565715A (es)
AU (1) AU2018354143A1 (es)
BR (1) BR112020008022A2 (es)
CA (1) CA3079952A1 (es)
CL (1) CL2020001108A1 (es)
CR (1) CR20200218A (es)
CU (1) CU20200039A7 (es)
EC (1) ECSP20027220A (es)
IL (1) IL274116A (es)
MX (1) MX2020004211A (es)
PE (1) PE20210166A1 (es)
PH (1) PH12020550476A1 (es)
RU (1) RU2020116649A (es)
SG (1) SG11202003675PA (es)
WO (1) WO2019083997A1 (es)
ZA (1) ZA202002663B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017220539A1 (de) 2017-11-17 2019-05-23 Zf Friedrichshafen Ag Verfahren zum Betreiben eines Systems aus einem landwirtschaftlichen Arbeitsfahrzeug und zumindest einem an diesem angeordneten Arbeitsgerät
WO2019108729A1 (en) * 2017-12-01 2019-06-06 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
JP2022504204A (ja) 2018-10-02 2022-01-13 ルネラ・バイオテック・インコーポレーテッド 老化細胞死誘導薬としてのアジスロマイシンおよびロキシスロマイシン誘導体
EP3976197A4 (en) 2019-05-24 2023-07-19 Lunella Biotech, Inc. THERAPEUTIC AGENTS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321558D0 (en) * 1993-10-19 1993-12-08 Radopath Ltd Anti-viral agents
JPH09309874A (ja) * 1996-05-21 1997-12-02 Fuji Photo Film Co Ltd ポジ型感光性組成物
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
KR20020016844A (ko) * 1999-07-16 2002-03-06 추후보정 반응성 산소 대사산물 저해제를 이용한 세포독성 림프구의활성화 및 보호
JP2002221787A (ja) * 2001-01-25 2002-08-09 Fuji Photo Film Co Ltd ポジ型感放射線性組成物
JP4098483B2 (ja) 2001-03-12 2008-06-11 富士フイルム株式会社 平版印刷版原版
JP2003207898A (ja) * 2001-11-08 2003-07-25 Fuji Photo Film Co Ltd ポジ型レジスト組成物
KR101003960B1 (ko) * 2003-08-22 2010-12-30 안티포딘 파마슈티칼스, 인코포레이티드 미토콘드리아 표적화 산화방지제로서 사용되는 미토퀴논 유도체를 포함하는 약제학적 조성물
JP2005091713A (ja) * 2003-09-17 2005-04-07 Fuji Photo Film Co Ltd ポジ型レジスト組成物及びそれを用いたパターン形成方法。
GB0329716D0 (en) * 2003-12-23 2004-01-28 Amersham Plc Radical trap
WO2005099721A2 (en) * 2004-04-15 2005-10-27 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
DE102007025423A1 (de) 2007-05-30 2008-12-04 Friedrich-Schiller-Universität Jena Triphenylphosphonium-Derivate zum gezielten Transport und Freisetzen von Substanzen in Mitochondrien sowie Verfahren zu deren Verwendung
JP2009057330A (ja) * 2007-08-31 2009-03-19 Aspion Kk ジフェニレンヨードニウム化合物
WO2009038656A1 (en) * 2007-09-17 2009-03-26 Kosta Steliou Mitochondria-targeting antioxidant therapeutics
EA201101639A1 (ru) * 2009-05-20 2012-06-29 Юниверсите Де Женев Ингибиторы митохондриальной активности клеток, инициирующих рак, и их применение
WO2013022278A2 (en) * 2011-08-08 2013-02-14 Hanall Biopharma Co., Ltd. N1-cyclic amine-n5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
RU2522557C1 (ru) * 2013-04-09 2014-07-20 государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) СПОСОБ ПОЛУЧЕНИЯ п-ИОДФЕНИЛЖИРНЫХ КИСЛОТ
US9896466B2 (en) 2013-04-24 2018-02-20 Kkcg Ag Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level
EP3016715A4 (en) * 2013-07-01 2017-02-08 University Of Georgia Research Foundation, Inc. Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy
WO2015156943A1 (en) * 2014-03-10 2015-10-15 Aravind Musuluri Augmenting search results
CN107137390A (zh) * 2017-06-09 2017-09-08 中国人民解放军第三军医大学第附属医院 氯化二亚苯基碘鎓在制备治疗细菌感染药物中的用途

Also Published As

Publication number Publication date
WO2019083997A1 (en) 2019-05-02
US20200246344A1 (en) 2020-08-06
JP2021500374A (ja) 2021-01-07
PE20210166A1 (es) 2021-01-28
RU2020116649A (ru) 2021-11-30
EP3700512A4 (en) 2021-08-11
KR20200069365A (ko) 2020-06-16
CR20200218A (es) 2020-12-23
ZA202002663B (en) 2022-06-29
US11497749B2 (en) 2022-11-15
PH12020550476A1 (en) 2021-03-15
BR112020008022A2 (pt) 2020-10-27
EP3700512A1 (en) 2020-09-02
CA3079952A1 (en) 2019-05-02
IL274116A (en) 2020-06-30
SG11202003675PA (en) 2020-05-28
AU2018354143A1 (en) 2020-05-14
CN111565715A (zh) 2020-08-21
ECSP20027220A (es) 2020-06-30
MX2020004211A (es) 2020-08-13
CU20200039A7 (es) 2021-03-11

Similar Documents

Publication Publication Date Title
CL2020001108A1 (es) Mitoflavoscinas: la fijación como objetivo de enzimas que contienen flavina elimina células madre cancerosas (cscs) al inhibir la respiración mitocondrial.
AR080454A1 (es) Fitocanabinoides en el tratamiento del cancer
CL2019002580A1 (es) Mitorriboscinas: compuestos terapéuticos basados en mitocondrias que fijan como objetivo células cancerosas, bacterias y levaduras patógenas.
EA201201648A1 (ru) Стимуляторы sgc
MX2016009898A (es) Tratamientos para acne resistente.
AR087956A1 (es) METODOS Y COMPOSICIONES QUE MODULAN ACETIL-CoA CARBOXILASA PARA EL CONTROL DE MALEZAS
AR088392A1 (es) Macrociclos peptidomimeticos
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
BR112014030418A2 (pt) tintas de jato de tinta curáveis por radiação e métodos de impressão por jato de tinta industrial
BR112017006526A2 (pt) composição e kits para inibição de infecção microbiana patogênica e métodos de usar os mesmos
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
GT201300258A (es) Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa
CL2019003708A1 (es) Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas.
BR112014000542A2 (pt) composições de peroxidase eosinofílica e métodos de uso das mesmas
CA2863600A1 (en) Modulators of acyl-coa lysocardiolipin acyltransferase 1 ( alcat1) and uses thereof
BR112018017077A2 (pt) terapias de combinação para tratamento de atrofia muscular espinhal
CL2023000061A1 (es) Macrociclos y su uso
BR112015022308A8 (pt) oligonucleotídeos antissenso para o tratamento de células-tronco cancerosas
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
MX2020000249A (es) Composiciones antimicrobianas efectivas contra bacterias y hongos.
CR20110023A (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
BR112021015222A2 (pt) Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1
BR112015025968A2 (pt) poliplexos
BR112012004768C8 (pt) usos de derivados de dioxolano e processo de tratamento do couro